Cencora (NYSE:COR) Posts Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Cencora (NYSE:COR) released its quarterly earnings data on Wednesday. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.21 by $0.13, reports. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $79.05 billion for the quarter, compared to analyst estimates of $77.68 billion. Cencora updated its FY 2025 guidance to 14.800-15.100 EPS and its FY25 guidance to $14.80-15.10 EPS.

Cencora Trading Up 0.9 %

Shares of NYSE COR traded up $2.15 on Friday, reaching $249.91. 240,361 shares of the company traded hands, compared to its average volume of 1,404,620. The company has a 50 day moving average of $231.77 and a 200 day moving average of $230.76. The stock has a market capitalization of $49.24 billion, a PE ratio of 32.99, a P/E/G ratio of 1.49 and a beta of 0.44. Cencora has a fifty-two week low of $191.11 and a fifty-two week high of $251.00. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.88%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Analysts Set New Price Targets

COR has been the topic of several recent research reports. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America reissued a “neutral” rating and issued a $245.00 target price (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.80% of the company’s stock.

Institutional Trading of Cencora

A number of institutional investors and hedge funds have recently bought and sold shares of COR. New Millennium Group LLC purchased a new position in Cencora in the 2nd quarter worth approximately $26,000. TCTC Holdings LLC purchased a new position in Cencora in the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC purchased a new position in Cencora in the 1st quarter worth approximately $30,000. MFA Wealth Advisors LLC purchased a new position in Cencora in the 2nd quarter worth approximately $30,000. Finally, Concord Wealth Partners purchased a new position in Cencora in the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.